Inclusion on the Pentagon’s 1260H list automatically makes WuXi AppTec one of the “biotechnology companies of concern” under the Biosecure Act. WuXi AppTec maintains that its place on the list was “clearly a mistake,” a spokesperson said.

Merck & Co. and Gilead are pulling the plug on the phase 3 Evoke-03 trial evaluating Trodelvy, combined with Keytruda, as a first-line treatment in patients with PD-L1-high non-small cell lung cancer.

A combination of Merck’s islatravir and Gilead’s lenacapavir has succeeded in two phase 3 trials and is in line to become the first long-acting oral HIV treatment that can be taken weekly.

The LinkedIn activities of AstraZeneca employees have yet again landed the drugmaker in hot water, with the U.K. marketing watchdog identifying eight breaches of its rules in the latest of a series of cases.

Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”

With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.